Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Relay Therapeutics Inc (Relay Therapeutics) is a clinical-stage precision medicine company. The company discovers and develops novel drugs for human use by focusing on small molecule medicines against precision medicine targets. It utilizes its proprietary Dynamo platform, which integrates leading-edge computational and experimental approaches to drug protein targets. The company's pipeline products include RLY-2608 for the treatment of breast cancer, solid tumors, and vascular malformations; RLY-8161 for solid tumors; αGal for fabry disease; and Lirafugratinib (RLY-4008). Relay Therapeutics is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
60 Hampshire Street, Cambridge, Massachusetts, 02139
Website
relaytx.com
Telephone
1 617 3708837
No of Employees
188
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RLAY (NASD)
Revenue (2024)
$10.0M
-60.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
1.2%
(2024 vs 2023)
Market Cap*
$1.7B
Net Profit Margin (2024)
XYZ
-152.1%
(2024 vs 2023)
* As of and is in US$
Relay Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Dynamo |
| RLY-2608: Breast Cancer and Solid Tumors | |
| RLY-2608: Vascular Malformations | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Relay Therapeutics Inc | Roche Holding AG | Merck & Co Inc | Novartis AG | Sanofi |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | Switzerland | France |
| City | Cambridge | Basel | Rahway | Basel | Paris |
| State/Province | Massachusetts | Basel-Stadt | New Jersey | Basel-Stadt | Ile-de-France |
| No. of Employees | 188 | 112,774 | 73,000 | 75,883 | 84,587 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Alexis Borisy | Chairman | Executive Board | 2015 | 53 |
| Sanjiv K. Patel, M.D. | Chief Executive Officer; Director; President | Executive Board | 2017 | 51 |
| Thomas Catinazzo | Chief Financial Officer | Senior Management | 2022 | 48 |
| Brian R. Adams | Chief Legal Officer | Senior Management | 2022 | 51 |
| Jim Watters, PhD | Chief Scientific Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer